Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.

导出原文传递

翻译打印收藏纠错

第一作者： Masataka,Sawaki

第一单位： Breast Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya-shi, Aichi, 464 8681, Japan.

作者： Masataka,Sawaki ^[1] ; Yasuaki,Muramatsu ^[2] ; Kanae,Togo ^[3] ; Thomas,Laurent ^[4] ; Hiroji,Iwata ^[1]

作者单位： Breast Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya-shi, Aichi, 464 8681, Japan. ^[1] Oncology Medical Affairs, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151 8589, Japan. ^[2] Corporate Affairs, Health & Value, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151 8589, Japan. ^[3] Clinical Study Support Inc., Daiei Bldg., 2F, 1-11-20, Nishiki, Naka-ku, Nagoya-shi, Aichi, 460 0003, Japan. ^[4]

关键词 advanced breast cancer complete blood count dose reduction endocrine therapy palbociclib real-world data

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);日本(Japan);哌嗪类(Piperazines);吡啶类(Pyridines)

DOI 10.2217/fon-2021-1448

PMID 35306859

发布时间 2023-01-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交